Skip to main content

Advertisement

Figure 2 | Diabetology & Metabolic Syndrome

Figure 2

From: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

Figure 2

Adjusted mean changes from baseline HbA 1c over 76 weeks (repeated-measures analysis). Randomized and treated patients. Patients who received placebo in the short-term period were switched to blinded metformin 500 mg at week 24. Titration of blinded metformin was not allowed. BL: baseline; HbA1c: glycated hemoglobin; PBO: placebo; SAXA: saxagliptin.

Back to article page